Brought to you by 
Ocera Therapeutics reverse merges with struggling public biotech Tranzyme
11 Sep 2020
Executive Summary
Struggling public biotech Tranzyme Inc. is reverse merging with privately held Ocera Therapeutics Inc. (developing drugs for liver disease, and marketing a device for IBS) in a stock-for-stock transaction. Each Ocera share will be exchanged for 1.538 Tranzyme shares (worth $0.71). The combined company, retaining the Ocera name and its San Diego corporate headquarters, will be owned in majority by existing Ocera investors (72.6%) and the rest by Tranzyme’s shareholders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ocera Therapeutics reverse merges with struggling public biotech Tranzyme
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice